Results 161 to 170 of about 12,148 (210)

Prevalence of hypoxemia among sick children, aged under-five years, seeking healthcare at primary health facilities in Uttar Pradesh, India: an observational-cohort study. [PDF]

Lancet Reg Health Southeast Asia
Awasthi S, Kumar D, Pandey AK, Agarwal GG, Jacob A, Sharma K, Agarwal M, Langet H, Kumar G, Levine GA, Cicconi S, Ruffo M, Emmanuel-Fabula M, Beynon F, Schär F, Wyss K, D'Acremont V, TIMCI Collaborator Group.   +17 more
europepmc   +1 more source

Geospatial Analysis of Accredited Lung Cancer Screening Facilities in Florida Reveals Suboptimal Alignment with High-Risk Populations. [PDF]

Cancer Res Commun
Komrokji SR, Ayzenshtat L, Sangi-Haghpeykar H, Ashraf N, Vermund SH, Schwarzberg A, Sommers KE, Hoang E, Sotomayor EM, Anderson ML.   +9 more
europepmc   +1 more source

Mathematical modeling of dopamine rhythms and timing of dopamine reuptake inhibitors. [PDF]

PLoS Comput Biol
Yao T, Kim R.
europepmc   +1 more source

Cebpa is required for haematopoietic stem and progenitor cell generation and maintenance in zebrafish. [PDF]

Open Biol
Chen K, Wu J, Zhang Y, Liu W, Chen X, Zhang W, Huang Z.   +6 more
europepmc   +1 more source

Enhanced methods for genetic assays in Drosophila cells

Wang Y, Lee J, Housden A, Hottinger E, Housden B.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anticancer Agents: VTA or VDA

Current Bioactive Compounds, 2009
The tumor vasculature is quite an attractive target for anti-cancer/anti-tumor therapy because the blood vessels provide the route for nutrient/waste and oxygen/carbon dioxide exchanges as well as a convenient route for tumor metastatic spread. The complex interplay of the tumor with the local blood vasculature is intriguing.
Paul Sebahar, J. Willardsen, Mark Anderson   +2 more
openaire   +1 more source

VDA-Kommunikation mit IBM PS/2: PS/2-DAX-Kommunikationssystem für VDA 4914

ZWF Zeitschrift Fuer Wirtschaftlichen Fabrikbetrieb, 1988
exaly   +2 more sources

Vascular Disrupting Agents (VDAs) in Anticancer Therapy

Current Clinical Pharmacology, 2010
Vascular disrupting agents (VDAs) represent a novel class of drugs targeting the tumor's blood supply. Conceptually and operationally different from currently used antiangiogenic agents, VDAs have a high specificity for the established but abnormal tumor vasculature.
Laura G M, Daenen, Jeanine M L, Roodhart, Yuval, Shaked, Emile E, Voest   +3 more
openaire   +2 more sources

Combination Therapy with Chemotherapy and VDAs

2010
A growing body of preclinical and clinical evidence substantiates the feasibility of combining vascular disrupting agents (VDAs) and conventional anticancer therapies. The enhanced disease response to this combination is attributable to the respective activity of VDAs on the tumor vasculature and of the cytotoxic drug on proliferating tumor cells ...
Giulia Taraboletti, Katiuscia Bonezzi, Raffaella Giavazzi   +2 more
openaire   +1 more source